Profile data is unavailable for this security.
About the company
Haleon plc is a consumer healthcare company. The Company's product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.
- Revenue in GBP (TTM)11.26bn
- Net income in GBP1.09bn
- Incorporated2021
- Employees24.00k
- LocationHaleon PLCBuilding 5, First Floor, The HeightsWEYBRIDGE KT13 0NYUnited KingdomGBR
- Phone+44 19 3282 2000
- Websitehttps://www.haleon.com/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
Biogen Inc | 7.23bn | 866.27m |
Bayer AG | 39.32bn | -1.06bn |
Otsuka Holdings Co Ltd | 11.46bn | 666.82m |
UCB SA | 4.55bn | 200.32m |
Jiangsu Hengrui Pharmaceuticals Co Ltd | 2.69bn | 578.64m |
Haleon PLC | 11.26bn | 1.09bn |
Takeda Pharmaceutical Co Ltd | 23.21bn | 788.30m |
Sun Pharmaceutical Industries Ltd | 4.39bn | 927.87m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Dodge & Coxas of 01 Sep 2024 | 238.18m | 2.61% |
The Vanguard Group, Inc.as of 01 Sep 2024 | 234.47m | 2.57% |
MFS International (UK) Ltd.as of 01 Sep 2024 | 152.24m | 1.67% |
BlackRock Fund Advisorsas of 01 Sep 2024 | 151.91m | 1.67% |
BlackRock Investment Management (UK) Ltd.as of 01 Sep 2024 | 149.25m | 1.64% |
Norges Bank Investment Managementas of 01 Sep 2024 | 142.60m | 1.56% |
Harding Loevner LPas of 01 Sep 2024 | 132.71m | 1.45% |
First Eagle Investment Management LLCas of 01 Sep 2024 | 128.80m | 1.41% |
GIC Pte Ltd. (Investment Management)as of 01 Sep 2024 | 111.48m | 1.22% |
Legal & General Investment Management Ltd.as of 01 Sep 2024 | 110.07m | 1.21% |